Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

ACCRU: Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=46 | Active, not recruiting | Sponsor: Academic and Community Cancer Research United | Trial completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

A rare side effect of brentuximab vedotin (ADO 2025) - No abstract available

Adverse events • Hematological Malignancies • Lymphoma • Oncology

Patients With Lymphoma Requiring Colectomy (SOHO 2025) - "He was treated with eight cycles of R-Hyper-CVAD and intrathecal cytarabine...He received three cycles of brentuximab vedotin with cyclophosphamide, etoposide, and prednisone without response. He next received two cycles of gemcitabine-oxaliplatin with progressive disease and developed fulminant pseudomembranous colitis in the setting of Clostridium difficile leading to total abdominal colectomy and end ileostomy. He then received two cycles of nivolumab when PDL1 expression resulted as 60%; however, he continued to decline and was transitioned to comfort measures...From the limited data that is published, intestinal diversion can be associated with septicemia, suboptimal nutrition, and poor outcomes. These cases illustrate the need for prompt adequate surgical management, which may lead to favorable outcomes as in our first case, and the development of preventive strategies to avoid outcomes such as the second case."

Clinical • IO biomarker • B Cell Lymphoma • Burkitt Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ALK • BCL2 • BCL6 • PD-L1

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy. (PubMed, Mol Cancer Ther) - "Taken together, TUB-010 is a novel, potential best-in-class anti-CD30 ADC with improved biophysical properties designed to deliver MMAE with higher precision and a wider therapeutic window than Adcetris using Tub-tag technology. Therefore, TUB-010 may increase the clinical benefit of anti-CD30 ADC therapies."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Progression-Free Survival and Overall Survival in Relapsed/Refractory T-cell Lymphoma Patients on Chemotherapy vs Targeted Therapy (SOHO 2025) - "Options include chemotherapy, brentuximab, pralatrexate, romidepsin, and duvelisib...Other treatment options used were immunotherapy (n = 2), tipifarnib (n = 2), pentostatin (n = 1), MEDI-570 (n = 1), duvelisib (n = 1), and vorinostat (n = 1)... Our study showed a benefit to the use of targeted therapy in relapsed/refractory TCL that was more pronounced in the third-line setting, likely due to increased resistance to chemotherapy with repeated exposure."

Clinical • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Management of Hodgkin Lymphoma in Older Patients (SOHO 2025) - "7 Intensive regimens, such as escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escBEACOPP), are generally contra-indicated in older adults due to a prohibitively high risk of treatment-related mortality. 8 The incorporation of modern agents, including brentuximab vedotin and immune checkpoint inhibitors such as nivolumab and pembrolizumab, has significantly altered the therapeutic landscape for older adults...For example, the S1826 study demonstrated that nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) can be safely administered to patients aged 60 years and older, with an efficacy comparable to that in the overall study population...6,9 More recently, the BRECADD regimen — which incorporates brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone — has been evaluated in a phase 2 study in older patients...Bröckelmann PJ, Bühnen I, Meissner..."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Pembrolizumab in Relapsed/Refractory Hodgkin Lymphoma: Institutional Experience at a High-Complexity Oncologic Center in Colombia (SOHO 2025) - "For these cases, anti-PD1 therapies such as nivolumab and pembrolizumab are approved, with pembrolizumab demonstrating a 72% overall response rate (ORR) and a 28% complete response rate in the KEYNOTE-087 study...Pembrolizumab was used as monotherapy in 38.8% and combined with regimens like GVD, ESHAP, or brentuximab vedotin in others... Pembrolizumab demonstrated high efficacy and a favorable safety profile in R/R HL patients."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Response to brentuximab vedotin in CTCL: How much CD30 is needed? (ADO 2025) - "Sponsored by Takeda"

Cutaneous T-cell Lymphoma • TNFRSF8

Real-World Outcomes of Salvage Chemotherapy in Adult Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis (SOHO 2025) - "Conventional salvage therapy (ICE, DHAP, ESHAP, GDP) and novel agent-based (brentuximab, nivolumab) salvage were used in 32.7% (n = 18) and 67.3% (n = 37), respectively. Novel salvage therapies followed by ASCT offer improved response rates and the potential for more durable disease control in R/R cHL."

Real-world • Real-world evidence • Retrospective data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study. (PubMed, J Dtsch Dermatol Ges) - "Brentuximab vedotin as monotherapy or combination therapy is a rapidly effective and tolerable treatment option for patients with cutaneous PTCL, although the duration of response is short."

Journal • Monotherapy • Retrospective data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients. (PubMed, Hemasphere) - No abstract available

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Moving Beyond Romidepsin: New Strategies for Relapsed/Refractory PTCL (SOHO 2025) - "Current FDA-approved agents include pralatrexate, 2 belinostat, 3 and brentuximab vedotin...In this study, romidepsin plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) was compared to CHOP in untreated T-cell lymphomas (TCLs) but failed to show an improvement in progression-free survival (PFS) — the primary endpoint of this study 6 Brentuximab vedotin has the highest response rate of 87% in R/R anaplastic large cell lymphoma (ALCL), 4 but the response rates are lower in other subtypes...7 Duvelisib — a dual PI3K delta/ gamma inhibitor — has shown an overall response rate (ORR) of 48%, a complete response (CR) rate of 33%, and a median duration of response of 7.89 months...Other PI3K inhibitors include tenalisib 10 and linperlisisb, 11 which demonstrate similar results...Inhibitors of the JAK/ STAT pathway like ruxolitinib are showing promising results in PTCL — both as single agents and in combination...The ORACLE study compared 5-azacitidine against..."

Oncology • Peripheral T-cell Lymphoma • CD5 • CD7 • CD70 • EZH2 • GATA3 • IL2RA • KLRD1 • SIRPA • TNFRSF8

Stage Migration and Survival Trends in Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Multiple Myeloma, 2000-2017: A SEER Analysis of 393, 058 Cases (SOHO 2025) - "Context: Over the past two decades, the therapeutic landscape of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM) has been transformed by targeted agents, including rituximab, brentuximab-vedotin, and proteasome inhibitors. In conclusion, survival has improved in HL, NHL, and MM, but not because of earlier detection. Instead, gains reflect therapeutic progress, while stage at diagnosis has worsened, especially in rural populations. These findings suggest that progress in treatment may have inadvertently deprioritized early diagnosis."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Survival Trends in T-cell Lymphomas in the Era of Novel Therapies: A National Cancer Database (NCDB) Study (SOHO 2025) - "Context: New drug approvals for T-cell lymphomas (TCLs) have been limited, including pralatrexate (2009), romidepsin (2011, withdrawn in 2022), and belinostat (2014) for peripheral TCL (PTCL), and brentuximab vedotin (2011) for anaplastic large cell lymphoma (ALCL). The OS has significantly improved in Era 2 for ALCL, possibly associated with approval of brentuximab vedotin. However, survival improvement was modest for PTCL/AITL, highlighting unmet needs for novel effective therapies."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: New York Medical College | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

First-in-Human, Open-Label, Phase 1 Study of CD30-Directed Antibody-Drug Conjugate (ADC) With a Topoisomerase 1 Inhibitor Payload, PF-08046044 (35C) in Patients With Relapsed/ Refractory Lymphomas: Safety and Preliminary Efficacy From Dose Escalation (SOHO 2025) - P1 | "35C shares its antibody backbone with brentuximab vedotin (BV). 35C demonstrated promising antitumor activity in heavily pretreated R/R cHL patients who progressed after prior BV and PD-1 inhibitors, as well as in R/R PTCL patients. Safety and tolerability were encouraging, and dose-escalation is ongoing."

Clinical • P1 data • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis. (PubMed, Br J Haematol) - "By multivariable analysis, pretransplant CPI resulted in the only independent predictor of relapse (hazard ratio [HR]: 0.124, 95% confidence interval 0.270-0.570, p = 0.007) and a strong predictor for PFS (HR 0.43, 95% CI 0.18-1.02, p = 0.057). Our findings support the use of CPI over BV as the first-line salvage therapy for R/R HL patients relapsing after autologous stem cell transplantation when consolidation with Allo-SCT is planned."

Checkpoint inhibition • Journal • Retrospective data • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Oncology • Transplantation

Clinical Efficacy and Safety of Pembrolizumab and Nivolumab in Frontline Treatment for Classical Hodgkin Lymphoma: A Systematic Review and Meta-Analysis (SOHO 2025) - " Nine phase 2/3 trials were included in the analysis; two investigated pembrolizumab in combination with doxorubicin, vinblastine, and dacarbazine (AVD), four investigated nivolumab with AVD, two investigated nivolumab with brentuximab vedotin (BV), and one investigated nivolumab with BV with doxorubicin and dacarbazine. The implementation of nivolumab or pembrolizumab in frontline treatment for newly diagnosed cHL can be a beneficial strategy in individuals with advanced disease or who are unfit for standard treatment."

Retrospective data • Review • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Duvelisib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results From the Phase 2 PRIMO Trial (SOHO 2025) - P2 | "Current monotherapies have overall response rates (ORR) of <30% (except brentuximab vedotin for CD30+ ALCL). PRIMO outcomes compare favorably to currently available single-agent options. AEs were generally manageable and consistent with those observed previously. PRIMO-EP results confirm duvelisib to be a promising agent for this disease with a high unmet need, poor prognosis, and limited effective treatments."

Clinical • P2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Outcomes of Patients With Anaplastic Large Cell Lymphoma Who Relapse Post-Brentuximab Vedotin (SOHO 2025) - "BV is approved in the front-line setting in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP), as well as in relapsed/refractory (r/r) ALCL. Patients who relapse following BV, either front-line or later, have poor outcomes. Novel therapies are needed for this high-risk patient population."

Clinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ALK

Survival in Patients With Advanced-Stage, High-Risk Hodgkin Lymphoma Treated With Conventional Chemotherapy Plus Brentuximab Vedotin and Nivolumab: 4-Year Follow-Up From a Phase 2 Trial (SOHO 2025) - "Background: Around 80% of patients with newly diagnosed, advanced stage (3/4) Hodgkin lymphoma (HL) are cured by the conventional chemotherapy ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or the escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen. Addition of nivolumab and brentuximab vedotin to conventional chemotherapy improved both response rate and overall survival for patients with advanced-stage, high IPS score Hodgkin lymphoma."

Clinical • Metastases • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab Vedotin-Induced Pulmonary Toxicities in Hodgkin Lymphoma Patients (SOHO 2025) - "Clinical Presentations: The first three patients were treated with BV, doxorubicin, vinblastine, and dacarbazine (AAVD)...Case 4: A 66-year-old male who had received 2 cycles of brentuximab, etoposide, vinblastine, and dacarbazine (AEVD) was admitted with respiratory symptoms and hypoxia... Pulmonary toxicity is a rare but life-threatening complication associated with BV treatment. A review of the reported case series did not reveal common potential risk factors. Further research and a larger case series are needed to understand the pathology and possible risk factors."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

From Jaundice to Lymphoma: Concurrent Bile Duct and Mediastinal Lymphoma Presenting as Obstructive Jaundice (ACG 2025) - "The patient was treated for Stage III unfavorable Hodgkin's lymphoma with chemotherapy (brentuximab + doxorubicin, vinblastine, dacarbazine) and biliary stent was removed after 7 weeks, resolving the bile duct mass and improving systemic disease and biliary obstruction. Definitive preoperative diagnosis of HL in the bile duct is challenging due to sampling difficulties. While HL generally has a favorable prognosis, the outcome for bile duct involvement remains uncertain due to its rarity, requiring further research.Figure: Figure A. ERCP: showing contrast filling defect at distal bile duct Figure B. MRCP: Showing stenosis of mid portion of the common bile duct with proximal dial action of biliary tract. Figure C. PET scan coronal view: Arrow head - mass in right mediastinum, Complete arrow - mass in bile duct Figure D. PET scan Transverse view: Mass in bile duct."

B Cell Lymphoma • Biliary Cancer • Cholangiocarcinoma • Cholestasis • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor • TNFRSF8

Transformed Mycosis Fungoides Into CD30-Negative Cutaneous Large T-Cell Lymphoma (SOHO 2025) - "However, absence of CD30 may indicate a more aggressive disease and limit the use of targeted therapies such as brentuximab vedotin...Follow-Up: Methotrexate was initiated with good tolerance... This case illustrates the aggressive behavior of large-cell transformed MF with CD30 negativity, which limits treatment options and is associated with poor prognosis. Median survival in similar cases is reported to be less than 12 months, particularly when CD30 expression is absent. In this patient, the late-stage diagnosis highlights the need for early detection and comprehensive care."

Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • ALK • CD20 • CD4 • CD5 • TNFRSF8

Efficacy of brentuximab vedotin in blood, lymph nodes, and skin: An analysis based on real-life data (ADO 2025) - "Sponsored by Takeda"

Clinical • Hematological Malignancies • Lymphoma • Oncology